Related Experiment Video
Updated: Jul 19, 2026

Experimental Autoimmune Uveitis: An Intraocular Inflammatory Mouse Model
Published on: January 12, 2022
Adalimumab for sight-threatening uveitis in Behçet's disease
B Mushtaq1, T Saeed, R D Situnayake
1Birmingham and Midland Eye Centre, Birmingham, UK.
Aims:
To describe the clinical outcome of three patients with Behçet's disease maintained on infliximab who were switched to adalimumab therapy.
Methods:
Case note review. Main outcome measure was recurrence of uveitis.
Results:
All patients remained free of recurrence with stable visual acuities.
Conclusions:
Adalimumab appears to maintain disease remission in Behçet's disease.
Related Concept Videos
Glaucoma: Overview
Open Angle Glaucoma: Treatment
Drugs such as carbonic anhydrase inhibitors, α2- and...
Angle Closure Glaucoma: Treatment
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Diabetic Retinopathy

